---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-071392"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:35:31.542255+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Helix shareholders approve all proposals for business combination with BridgeBio Oncology Therapeutics

## Summary
- Business Combination Proposal approved: 17.3M FOR, 2.1M AGAINST (82.55% quorum).
- Domestication to Delaware, new charter and bylaws, name change to BridgeBio Oncology Therapeutics Inc. approved.
- All 9 director nominees elected unanimously with 19.4M votes each; effective at closing.
- 2025 Stock Option and Incentive Plan and Employee Stock Purchase Plan both approved by shareholders.

## SEC filing metadata
- accession: 0001213900-25-071392
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000121390025071392/0001213900-25-071392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000121390025071392/ea0251413-8k425_helix2.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-071392
- JSON: https://secwatch.observer/filing/0001213900-25-071392.json
- Plain text: https://secwatch.observer/filing/0001213900-25-071392.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.